An immunotherapeutic drug called BO-112, which was developed in Spain, proved to be effective in treating different types cancer in the first phase of the Phase I study. The study objective, in which 28 patients with solid tumors – including lung cancer, renal cancer and melanoma – attended, was to check the safety and efficacy of this molecule, both individually, as well in combination with anti-PD-1 antibodies in patients who did not respond to these drugs.
The research, which included Gregorio Marañón Hospital, Clínica de Navarra Hospital and Ramón y Cajal Hospital and which was presented at the European Congress of Medical Oncology in Munich, showed that immunotherapy in which BO-112 was combined with anti-PD1 antibodies (nivolumab or pembrolizumab), managed to control the disease in 58% of patients and to reduce tumor size in 17% of cases without causing serious side effects.
New immunotherapy combines experimental molecule BO-112 with anti-PD1 antibodies (nivolumab or pembrolizumab)
This drug is administered intratumorally, that is injected directly into the tumor lesion so that, as Gregorio Marañón Iván Márquez Rodas, oncologist explains, causes a tumor-responsive and also pro-inflammatory response so that the immune system recognizes the tumor and triggers the response immune.
The anticancer molecule in the BO-112 experimental phase, which has just demonstrated its potential to fight against resistant cancer – between 30 and 50% of patients treated with PD1 antibodies do not have a favorable response to them – was discovered in 2008, and researchers will continue to study its safety profile and earthquakes and will also test if it is effective in other types of tumors.
Although the results are hopeful, experts point out that they are still preliminary, so they need to be confirmed in new studies, and that is why seven Spanish hospitals are responsible for recruiting new patients to whom anti-PD1 has not worked.